M K Pugsley

Summary

Affiliation: XOMA (US) LLC
Country: USA

Publications

  1. ncbi The diverse molecular mechanisms responsible for the actions of opioids on the cardiovascular system
    Michael K Pugsley
    Department of Pharmacology and Toxicology, XOMA US LLC, 2910 Seventh Street, Berkeley, CA 94710, USA
    Pharmacol Ther 93:51-75. 2002
  2. ncbi Sodium channel blocking and antiarrhythmic actions of the novel arylpiperazine rsd992
    Eric S Hayes
    Department of Pharmacology and Therapeutics, The University of British Columbia, Room 413, 2176 Health Sciences Mall, Vancouver, Canada V8V 3L2
    Pharmacol Res 46:19-27. 2002
  3. ncbi The vascular system. An overview of structure and function
    M K Pugsley
    Department of Pharmacology and Toxicology, XOMA US LLC, Berkeley, CA 94710, USA
    J Pharmacol Toxicol Methods 44:333-40. 2000
  4. ncbi Etanercept. Immunex
    M K Pugsley
    Department of Pharmacology, XOMA US LLC, Berkeley, CA 94710, USA
    Curr Opin Investig Drugs 2:1725-31. 2001
  5. ncbi Inhibitors of the complement system currently in development for cardiovascular disease
    M K Pugsley
    Department of Pharmacology, XOMA US LLC, Berkeley, CA 94710, USA
    Cardiovasc Toxicol 3:43-70. 2003
  6. ncbi Protamine is a low molecular weight polycationic amine that produces actions on cardiac muscle
    Michael K Pugsley
    Department of Pharmacology, XOMA US LLC, 2910 Seventh St, Berkeley, CA 94710, USA
    Life Sci 72:293-305. 2002
  7. ncbi Commercial development considerations for biotechnology-derived therapeutics
    B J Marafino
    Department of Comparative Medicine, XOMA (US) LLC, Berkeley, CA 94710, USA
    Cardiovasc Toxicol 3:5-12. 2003
  8. ncbi A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker
    David E Mire
    New Product Planning, Sankyo Pharma Inc, Parsippany, New Jersey, USA
    J Cardiovasc Pharmacol 46:585-93. 2005
  9. ncbi The opioid receptor independent actions of kappa receptor agonists in the cardiovascular system
    Michael K Pugsley
    Forest Research Institute, Pharmacology, Harborside Financial Center, Plaza V, 19th Floor, Jersey City, NJ 07311 4994, USA
    Curr Pharm Des 10:2429-44. 2004
  10. ncbi The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes
    Michael K Pugsley
    Pharmacology, Forest Research Institute, Jersey City, NJ 07311, USA
    Proc West Pharmacol Soc 48:35-8. 2005

Collaborators

Detail Information

Publications10

  1. ncbi The diverse molecular mechanisms responsible for the actions of opioids on the cardiovascular system
    Michael K Pugsley
    Department of Pharmacology and Toxicology, XOMA US LLC, 2910 Seventh Street, Berkeley, CA 94710, USA
    Pharmacol Ther 93:51-75. 2002
    ..In many instances, it would appear that the effects of opioid agonists (and antagonists) in cardiovascular disease models may be mediated by opioid receptor-independent actions of these drugs...
  2. ncbi Sodium channel blocking and antiarrhythmic actions of the novel arylpiperazine rsd992
    Eric S Hayes
    Department of Pharmacology and Therapeutics, The University of British Columbia, Room 413, 2176 Health Sciences Mall, Vancouver, Canada V8V 3L2
    Pharmacol Res 46:19-27. 2002
    ..RSD992 exhibits frequency- and ischaemia-selective actions on myocardial sodium currents and antiarrhythmic actions in ischaemic rat myocardium...
  3. ncbi The vascular system. An overview of structure and function
    M K Pugsley
    Department of Pharmacology and Toxicology, XOMA US LLC, Berkeley, CA 94710, USA
    J Pharmacol Toxicol Methods 44:333-40. 2000
    ....
  4. ncbi Etanercept. Immunex
    M K Pugsley
    Department of Pharmacology, XOMA US LLC, Berkeley, CA 94710, USA
    Curr Opin Investig Drugs 2:1725-31. 2001
    ..1 million). It was also reported that if launched for CHF, an estimated peak year revenue was likely to be US $500 million. The company maintains a website containing additional information about etanercept at http://www.enbrelinfo.com...
  5. ncbi Inhibitors of the complement system currently in development for cardiovascular disease
    M K Pugsley
    Department of Pharmacology, XOMA US LLC, Berkeley, CA 94710, USA
    Cardiovasc Toxicol 3:43-70. 2003
    ....
  6. ncbi Protamine is a low molecular weight polycationic amine that produces actions on cardiac muscle
    Michael K Pugsley
    Department of Pharmacology, XOMA US LLC, 2910 Seventh St, Berkeley, CA 94710, USA
    Life Sci 72:293-305. 2002
    ....
  7. ncbi Commercial development considerations for biotechnology-derived therapeutics
    B J Marafino
    Department of Comparative Medicine, XOMA (US) LLC, Berkeley, CA 94710, USA
    Cardiovasc Toxicol 3:5-12. 2003
    ....
  8. ncbi A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker
    David E Mire
    New Product Planning, Sankyo Pharma Inc, Parsippany, New Jersey, USA
    J Cardiovasc Pharmacol 46:585-93. 2005
    ..Inferential pharmacological studies compare and contrast the effects of olmesartan to those of other ARBs in comparable preclinical animal models...
  9. ncbi The opioid receptor independent actions of kappa receptor agonists in the cardiovascular system
    Michael K Pugsley
    Forest Research Institute, Pharmacology, Harborside Financial Center, Plaza V, 19th Floor, Jersey City, NJ 07311 4994, USA
    Curr Pharm Des 10:2429-44. 2004
    ..In many instances it would appear that the effects of opioid agonists (and antagonists) in cardiovascular disease models of ischaemia may be mediated by opioid receptor-independent actions of these drugs...
  10. ncbi The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes
    Michael K Pugsley
    Pharmacology, Forest Research Institute, Jersey City, NJ 07311, USA
    Proc West Pharmacol Soc 48:35-8. 2005
    ..These studies show that the antihypertensive affect of OM is renoprotective but suggest that these renal benefits may also occur independently from a reduction in BP. A further evaluation of the effects of OM in diabetes is warranted...